Serum Chemerin Levels are Associated with Visceral Adiposity, Independent of Waist Circumference, in Newly Diagnosed Type 2 Diabetic Subjects
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Chemerin has been suggested to be linked to insulin resistance and type 2 diabetes mellitus (T2DM). However, the relationshipbetween visceral adiposity and chemerin levels remains unclear in subjects with T2DM. In this study, we investigated the relationship between serum chemerin levels and visceral adiposity. Materials and Methods: This study included 102 subjects newly diagnosed with T2DM. The relationships between serum chemerin levels and clinical and biochemical parameters were examined. Multiple linear regression analysis was performed to determine the predictable factors of serum chemerin levels. Results: Serum chemerin levels showed significant positive correlations with body mass index (BMI), waist circumference (WC), visceral fat thickness (VFT), insulin levels, the homeostasis model assessment of insulin resistance, and levels of triglycerides (log-transformed) and high-sensitivity C-reactive protein, while showing significant negative correlations with high-density lipoproteincholesterol. After adjusting for BMI and WC, VFT showed a significant relationship with serum chemerin levels (r=0.222, p=0.027). Moreover, VFT was an independent predictive factor of serum chemerin levels (β=0.242, p=0.041). Conclusion: We demonstrated that chemerin is linked to metabolic syndrome components. Moreover, serum chemerin levels were associated significantly with obesity, especially visceral adipose tissue, in subjects with T2DM.
Abstract
Purpose: Chemerin has been suggested to be linked to insulin resistance and type 2 diabetes mellitus (T2DM). However, the relationshipbetween visceral adiposity and chemerin levels remains unclear in subjects with T2DM. In this study, we investigated the relationship between serum chemerin levels and visceral adiposity. Materials and Methods: This study included 102 subjects newly diagnosed with T2DM. The relationships between serum chemerin levels and clinical and biochemical parameters were examined. Multiple linear regression analysis was performed to determine the predictable factors of serum chemerin levels. Results: Serum chemerin levels showed significant positive correlations with body mass index (BMI), waist circumference (WC), visceral fat thickness (VFT), insulin levels, the homeostasis model assessment of insulin resistance, and levels of triglycerides (log-transformed) and high-sensitivity C-reactive protein, while showing significant negative correlations with high-density lipoproteincholesterol. After adjusting for BMI and WC, VFT showed a significant relationship with serum chemerin levels (r=0.222, p=0.027). Moreover, VFT was an independent predictive factor of serum chemerin levels (β=0.242, p=0.041). Conclusion: We demonstrated that chemerin is linked to metabolic syndrome components. Moreover, serum chemerin levels were associated significantly with obesity, especially visceral adipose tissue, in subjects with T2DM.
참고문헌 (32)
- 김철식, "Prevalence, Awareness, and Management of Obesity in Korea: Data from the Korea National Health and Nutrition Examination Survey (1998–2011)", Diabetes and Metabolism Journal, 38(1), pp.35~43 (2014), 대한당뇨병학회[DOI]
- Zheng W, "Association between body-mass index and risk of death in more than 1 million Asians", N Engl J Med, 364, pp.719~729 (2011)
- Larsson B, "Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913", Br Med J (Clin Res Ed), 288, pp.1401~1404 (1984)
- 김대중, "Visceral Fat Mass Has Stronger Associations with Diabetes and Prediabetes than Other Anthropometric Obesity Indicators among Korean Adults", Yonsei Medical Journal, 57(3), pp.674~680 (2016), 연세대학교의과대학[DOI]
- Ducimetiere P, "The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective study", Int J Obes, 10, pp.229~240 (1986)
- Bozaoglu K, "Chemerin is a novel adipokine associated with obesity and metabolic syndrome", Endocrinology, 148, pp.4687~4694 (2007)
- Goralski KB, "Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism", J Biol Chem, 282, pp.28175~28188 (2007)
- Yang M, "Elevated plasma levels of chemerin in newly diagnosed type 2 diabetes mellitus with hypertension", J Investig Med, 58, pp.883~886 (2010)
- Bozaoglu K, "Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population", J Clin Endocrinol Metab, 94, pp.3085~3088 (2009)
- Shin HY, "Chemerin levels are positively correlated with abdominal visceral fat accumulation", Clin Endocrinol (Oxf), 77, pp.47~50 (2012)
- 한주영, "Serum Chemerin Levels Are Associated with Abdominal Visceral Fat in Type 2 Diabetes", Journal of Korean Medical Science, 31(6), pp.924~931 (2016), 대한의학회
- Oh SW, "Cut-off point of BMI and obesity-related comorbidities and mortality in middle-aged Koreans", Obes Res, 12, pp.2031~2040 (2004)
- Lee SY, "Appropriate waist circumference cutoff points for central obesity in Korean adults", Diabetes Res Clin Pract, 75, pp.72~80 (2007)
- Weigert J, "Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes", Clin Endocrinol (Oxf), 72, pp.342~348 (2010)
- Ridker PM, "High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease", Circulation, 103, pp.1813~1818 (2001)
- Muruganandan S, "Chemerin, a novel peroxisome proliferator-activated receptor gamma (PPARgamma) target gene that promotes mesenchymal stem cell adipogenesis", J Biol Chem, 286, pp.23982~23995 (2011)
- Esteghamati A, "Pioglitazone and metformin are equally effective in reduction of chemerin in patients with type 2 diabetes", J Diabetes Investig, 5, pp.327~332 (2014)
- Hu W, "Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients", Diabetes Res Clin Pract, 91, pp.159~163 (2011)
- Wittamer V, "Specific recruitment of antigen-presenting cells by chemerin, a novel processed ligand from human inflammatory fluids", J Exp Med, 198, pp.977~985 (2003)
- Lehrke M, "Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis", Eur J Endocrinol, 161, pp.339~344 (2009)
- Ernst MC, "Chemerin: at the crossroads of inflammation and obesity", Trends Endocrinol Metab, 21, pp.660~667 (2010)
- Stejskal D, "Chemerin is an independent marker of the metabolic syndrome in a Caucasian population--a pilot study", Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 152, pp.217~221 (2008)
- Jialal I, "Increased chemerin and decreased omentin-1 in both adipose tissue and plasma in nascent metabolic syndrome", J Clin Endocrinol Metab, 98, pp.E514~E517 (2013)
- Gu P, "Chemerin is associated with inflammatory markers and metabolic syndrome phenotypes in hypertension patients", Clin Exp Hypertens, 36, pp.326~332 (2014)
- 하유진, "Relationship between Chemerin Levels and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease", Diabetes and Metabolism Journal, 35(3), pp.248~254 (2011), 대한당뇨병학회
- Lin X, "Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with type 2 diabetes", Clin Lab, 58, pp.539~544 (2012)
- Chaowalit N, "Subepicardial adipose tissue and the presence and severity of coronary arterydisease", Atherosclerosis, 186, pp.354~359 (2006)
- Stevens-Simon C, "A comparison of four techniques for measuring central adiposity in postpartum adolescents", J Matern Fetal Med, 10, pp.209~213 (2001)
- Shen W, "Visceral adipose tissue: relations between single-slice areas and total volume", Am J Clin Nutr, 80, pp.271~278 (2004)
- Stolk RP, "Ultrasound measurements of intraabdominal fat estimate the metabolic syndrome better than do measurements of waist circumference", Am J Clin Nutr, 77, pp.857~860 (2003)
- Kim SK, "Visceral fat thickness measured by ultrasonography can estimate not only visceral obesity but also risks of cardiovascular and metabolic diseases", Am J Clin Nutr, 79, pp.593~599 (2004)
- Hirooka M, "A technique for the measurement of visceral fat by ultrasonography: comparison of measurements by ultrasonography and computed tomography", Intern Med, 44, pp.794~799 (2005)